1. Portada
  2. Publicaciones y Patentes
  3. Publicaciones
  4. Hospital Universitario Fundación Alcorcón (FHA)

Hospital Universitario Fundación Alcorcón (FHA)

  1. A restricted population of CB1 cannabinoid receptors with neuroprotective activity. Chiarlone A, Bellocchio L, Blázquez C, Resel E, Soria-Gómez E, Cannich A, Ferrero JJ, Sagredo O, Benito C, Romero J, Sánchez-Prieto J, Lutz B, Fernández-Ruiz J, Galve-Roperh I, Guzmán M. Proc Natl Acad Sci U S A. 2014 Jun 3;111(22):8257-62.
  2. Endocannabinoid-hydrolysing enzymes in the post-mortem cerebellum of humans affected by hereditary autosomal dominant ataxias. Rodríguez-Cueto C, Benito C, Romero J, Hernández-Gálvez M, Gómez-Ruiz M, Fernández-Ruiz J. Pathobiology. 2014;81(3):149-59.
  3. Changes in CB(1) and CB(2) receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias. Rodríguez-Cueto C, Benito C, Fernández-Ruiz J, Romero J, Hernández-Gálvez M, Gómez-Ruiz M. Br J Pharmacol. 2014 Mar;171(6):1472-89.
  4. Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: role of 5HT(1A) and CB2 receptors. Pazos MR, Mohammed N, Lafuente H, Santos M, Martínez-Pinilla E, Moreno E, Valdizan E, Romero J, Pazos A, Franco R, Hillard CJ, Alvarez FJ, Martínez-Orgado J. Neuropharmacology. 2013 Aug;71:282-91.
  5. β-Amyloid exacerbates inflammation in astrocytes lacking fatty acid amide hydrolase through a mechanism involving PPAR-α, PPAR-γ and TRPV1, but not CB₁ or CB₂ receptors. Benito C, Tolón RM, Castillo AI, Ruiz-Valdepeñas L, Martínez-Orgado JA, Fernández-Sánchez FJ, Vázquez C, Cravatt BF, Romero J. Br J Pharmacol. 2012 Jun;166(4):1474-89.
  6. Prospects for cannabinoid therapies in basal ganglia disorders. Fernández-Ruiz J, Moreno-Martet M, Rodríguez-Cueto C, Palomo-Garo C, Gómez-Cañas M, Valdeolivas S, Guaza C, Romero J, Guzmán M, Mechoulam R, Ramos JA. Br J Pharmacol. 2011 Aug;163(7):1365-78.
  7. Cannabidiol reduces lipopolysaccharide-induced vascular changes and inflammation in the mouse brain: an intravital microscopy study. Ruiz-Valdepeñas L, Martínez-Orgado JA, Benito C, Millán A, Tolón RM, Romero J. J Neuroinflammation. 2011 Jan 18;8(1):5.
  8. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington"s disease. Blázquez C, Chiarlone A, Sagredo O, Aguado T, Pazos MR, Resel E, Palazuelos J, Julien B, Salazar M, Börner C, Benito C, Carrasco C, Diez-Zaera M, Paoletti P, Díaz-Hernández M, Ruiz C, Sendtner M, Lucas JJ, de Yébenes JG, Marsicano G, Monory K, Lutz B, Romero J, Alberch J, Ginés S, Kraus J, Fernández-Ruiz J, Galve-Roperh I, Guzmán M. Brain. 2011 Jan;134(Pt 1):119-36.